Q4 2019
Released Mar 27, 2020, before the open
10-K filed Mar 27, 2020, 87 days after period end · 0001171843-20-002061
Q4 2019 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$2.50K$2.50K derived±0.0% vs Q4 2018±0.0% vs Q3 2019
Net Income-$2.04M-$2.04M derivedN/M vs Q4 2018N/M vs Q3 2019
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$2,132,573N/M
Operating Cash Flowderived-$2,048,932N/M
Margins · derived
Operating margin-85302.9%−13110.3 pt vs Q4 2018
Net margin-81504.2%−68691.4 pt vs Q4 2018
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-K.
Same quarter
| Metric | Q4 2019dderived from reported figures | Q4 2018dderived from reported figures | Q4 2017dderived from reported figures | Q4 2016dderived from reported figures |
|---|---|---|---|---|
| Revenue | $2.50K | $2.50K | $252.50K | $8.75K |
| Net Income | -$2.04M | -$320.32K | -$3.32M | -$5.40M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Palisade Bio, Inc. · CIK 1357459 · Engraved from SEC EDGAR